Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225910 | 0.86 | P2RX7 (0.39) | — | |
| SCHEMBL1833105 | 0.84 | MTOR (0.41) | MTORNR1H2PARP1TNKS2PARP2 | |
| SCHEMBL21003285 | 0.84 | P2RX7 (0.41) | — | |
| SCHEMBL30993160 | 0.80 | NR1H2 (0.39) | MTORNR1H2PARP1TNKS2PARP2 | |
| SCHEMBL16033934 | 0.78 | P2RX7 (0.57) | PARP1TNKS2PARP2MKNK1MAPT | |
| SCHEMBL16033728 | 0.77 | P2RX7 (0.57) | NR1H2PARP1TNKS2PARP2MKNK1 | |
| SCHEMBL31518819 | 0.77 | ADORA1 (0.46) | NR1H2PARP1TNKS2PARP2MKNK1 | |
| SCHEMBL31598368 | 0.77 | MAPT (0.46) | MTORNR1H2PARP1TNKS2PARP2 | |
| SCHEMBL29899469 | 0.77 | MTOR (0.55) | MTORMAPTUSP2SMN1; SMN2 | |
| SCHEMBL9951760 | 0.77 | ESR2 (0.48) | NR1H2PARP1TNKS2PARP2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-08 | — | — | US | disclosed |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | PDE4A, PDE5A, PDE3A | MTOR 2365/4885NR1H2 2053/4885PARP1 92/4885 |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | MTOR 2365/4885NR1H2 2053/4885PARP1 92/4885 |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | MTOR 2365/4885NR1H2 2053/4885PARP1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.